These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6319918)

  • 1. Effects of the opioid benzodiazepine tifluadom and its optical isomers on spontaneous locomotor activity of mice.
    Ruhland M; Zeugner H
    Life Sci; 1983; 33 Suppl 1():631-4. PubMed ID: 6319918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locomotor depression by the opioid benzodiazepine tifluadom in mice.
    Castellano C; Pavone F; Sansone M
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):318-23. PubMed ID: 6091579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid benzodiazepine tifluadom and drug-induced hyperactivity in mice: lack of benzodiazepine-like effects.
    Sansone M; Castellano C; Pavone F; Hano J
    Pol J Pharmacol Pharm; 1985; 37(5):585-90. PubMed ID: 2870483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of the two isomers of the opioid benzodiazepine tifluadom with mu-, delta-, and kappa-binding sites and their analgesic and intestinal effects in rats.
    Petrillo P; Amato M; Tavani A
    Neuropeptides; 1985 Feb; 5(4-6):403-6. PubMed ID: 2860598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):334-42. PubMed ID: 1309877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of opioid subtypes compared with benzodiazepines in the staircase paradigm.
    Milman A; Weizman R; Rigai T; Rice KC; Pick CG
    Behav Brain Res; 2006 Jun; 170(1):141-7. PubMed ID: 16574254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of kappa-opioid receptor agonists on locomotor activity and memory processes in mice.
    Castellano C; Ammassari-Teule M; Libri V; Pavone F
    Pol J Pharmacol Pharm; 1988; 40(5):507-13. PubMed ID: 2855367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa-opioid diuretic effects of tifluadom, a benzodiazepine opioid agonist.
    Leander JD
    J Pharm Pharmacol; 1984 Aug; 36(8):555-6. PubMed ID: 6148404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a kappa-agonist-like antinociceptive action of tifluadom.
    Upton N; Gonzalez JP; Sewell RD
    Neuropharmacology; 1983 Oct; 22(10):1241-2. PubMed ID: 6316195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tifluadom-induced diuresis in rats. Evidence for an opioid receptor-mediated central action.
    Shearman GT; Tolcsvai L
    Neuropharmacology; 1986 Aug; 25(8):853-6. PubMed ID: 3022178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected opioid activity in a known class of drug.
    Römer D; Büscher HH; Hill RC; Maurer R; Petcher TJ; Zeugner H; Benson W; Finner E; Milkowski W; Thies PW
    Life Sci; 1982 Sep 20-27; 31(12-13):1217-20. PubMed ID: 6292610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse stereoselectivity of opiate and benzodiazepine receptors for the opioid benzodiazepine tifluadom.
    Kley H; Scheidemantel U; Bering B; Müller WE
    Eur J Pharmacol; 1983 Mar; 87(4):503-4. PubMed ID: 6303803
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of the opioid-benzodiazepine, tifluadom, on ingestive behaviors.
    Morley JE; Levine AS; Grace M; Kneip J; Zeugner H
    Eur J Pharmacol; 1983 Sep; 93(3-4):265-9. PubMed ID: 6315453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kappa-opiate-induced diuresis and changes in blood pressure: demonstration of receptor stereoselectivity using (+)- and (-)-tifluadom.
    Ureta H; López LF; Pérez A; Huidobro-Toro JP
    Eur J Pharmacol; 1987 Mar; 135(3):289-95. PubMed ID: 3034631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tifluadom (KC 5103) induces suppression and latency changes on somatosensory evoked potentials which are reversed by opioid antagonists.
    Freye E; Hartung E; Schenk GK
    Life Sci; 1983; 33 Suppl 1():537-40. PubMed ID: 6319908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal antinociceptive actions and naloxone reversibility of intravenous mu- and kappa-opioids in spinalized rats: potency mismatch with values reported for spinal administration.
    Parsons CG; West DC; Headley PM
    Br J Pharmacol; 1989 Oct; 98(2):533-43. PubMed ID: 2555012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist.
    Chang RS; Lotti VJ; Chen TB; Keegan ME
    Neurosci Lett; 1986 Dec; 72(2):211-4. PubMed ID: 3027627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
    Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
    J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.